If you have been told you have soft plaque in a coronary artery and you have spent the past few weeks mentally auditing every meal you have eaten for the last decade, you are not alone. Most people assume arterial plaque is the result of choices: too much butter, too little exercise, too many years of eating the wrong things.
Sometimes that is part of the story, but sometimes it is not. And if genetics is driving your cholesterol, the way you fight it changes significantly. One of the things that changes, perhaps unexpectedly, is that the cake may not actually be the main problem.
Why Do Doctors Bring Up Genetics After a Cardiac Finding?
A cardiologist starts thinking about genetics when the numbers do not match the lifestyle. Someone who eats well, exercises, has never smoked, and maintains a healthy weight develops significant soft plaque in a major coronary artery. Or someone’s LDL comes back persistently and severely elevated despite genuine dietary changes. Or the finding arrives earlier in life than the typical pattern of atherosclerosis would predict.
These mismatches raise a specific question: Is the liver producing too much LDL cholesterol on its own, regardless of what this person eats? If the answer is yes, the treatment conversation starts from a different place. Research also suggests that people with genetically high cholesterol tend to accumulate cardiovascular risk earlier and more steeply than people whose high cholesterol is primarily lifestyle-driven, since the exposure to elevated LDL starts from birth rather than developing gradually over decades.
The Main Genetic Heart Disease Conditions Involved
Familial Hypercholesterolemia
What is familial hypercholesterolemia? Usually called FH, it is an inherited condition that affects how the body processes LDL cholesterol. In people with FH, the liver lacks the normal number of functional LDL receptors, the proteins that pull LDL out of the bloodstream and clear it. As a result, LDL accumulates in the blood from birth, regardless of diet, and stays elevated throughout life.
FH is more common than most people think. It affects roughly 1 in 250 people, which makes it one of the most prevalent inherited conditions in existence and one of the most underdiagnosed. Many people with FH have no idea they have it until a cardiac event or an unexpected imaging finding prompts a deeper look.
The consequences of decades of elevated LDL from birth are significant. People with FH accumulate plaque far earlier than the general population, and the plaque they accumulate tends to be the soft, lipid-rich kind that carries the highest rupture risk. This is why a cardiac finding in someone without obvious lifestyle risk factors often leads a cardiologist to test for FH.
FH follows an autosomal dominant inheritance pattern, meaning one copy of the mutation is enough to cause the condition. If a parent has FH, each child has a 50 percent chance of inheriting it. A finding in one person is often a prompt to screen others in the family.
Lipoprotein(a) and Cardiovascular Disease Risk
Lipoprotein(a), written as Lp(a), is a cholesterol particle almost entirely determined by genetics. Unlike LDL, which is influenced meaningfully by diet and lifestyle, your Lp(a) level is set largely by the genes you were born with. Standard lipid panels do not measure it. Most people have never had their Lp(a) tested.
Elevated Lp(a) is a significant and independent cardiovascular risk factor. It promotes both plaque formation and blood clotting, a particularly dangerous combination in the context of soft plaque, which is the type most vulnerable to rupture. Someone can have a normal LDL and still carry substantially elevated cardiovascular risk because of high Lp(a), and that risk would be invisible on a routine cholesterol panel.
A single blood test measures Lp(a). If the result is elevated, it changes the clinical picture in important ways, particularly around how aggressively to treat LDL and whether the patient might be a candidate for clinical trials of new medications that specifically target Lp(a).
Polygenic Risk
Not all genetic cardiovascular risk comes from a single gene mutation. Some people carry a constellation of small genetic variants, each individually modest in effect, that together add up to meaningfully elevated risk. This is called polygenic risk, and it can be captured by testing that looks across many genetic variants simultaneously.
Polygenic risk scores do not diagnose a single condition the way FH testing does. They provide a risk estimate that helps a clinician calibrate how aggressively to treat, particularly in patients who sit in an ambiguous zone on standard risk calculators.
What Does a Heart Disease Genetic Test Actually Involve?
In most cases, genetic testing for cardiovascular risk requires only a blood draw. Results typically take two to four weeks. Testing may look specifically for FH-causing mutations, measure Lp(a) levels, assess polygenic risk, or some combination of the three, depending on what the cardiologist suspects and what the patient’s clinical picture suggests.
Coverage varies. For patients with a clear clinical indication, such as a cardiac finding that does not fit their apparent lifestyle risk, a strong family history of early heart disease, or severely elevated LDL that has not responded to standard treatment, insurers including Medicare often cover genetic testing. A care team can help clarify what documentation is needed.
How a Genetic Cause Changes Treatment Priorities
Statins, PCSK9 Inhibitors, and Familial Hypercholesterolemia Treatment
Medication becomes the primary tool, not the backup. For someone whose soft plaque is driven by lifestyle factors, the treatment conversation often starts with diet and exercise and adds medication if those measures are not sufficient. For someone with FH or significantly elevated Lp(a), that sequence is reversed. Medication comes first, and it comes in aggressively, because the underlying problem is not primarily what the person is eating. It is what the liver is producing.
High-intensity statins are the starting point for familial hypercholesterolemia treatment. For many FH patients, statins alone are not enough to bring LDL to the targets needed to stabilize and reduce plaque. PCSK9 inhibitors are particularly effective for FH and are generally used alongside a statin rather than in place of one, since the two medications lower LDL through different mechanisms. These drugs block a protein that degrades LDL receptors, allowing the liver to clear more LDL from the bloodstream. They can reduce LDL by 50 to 60 percent on top of whatever a statin achieves, and they are now covered by Medicare for patients who meet clinical criteria. For Lp(a), PCSK9 inhibitors offer a modest reduction as a secondary effect, but medications designed to target lipoprotein(a) directly are further along, several are now in late-stage clinical development and showing significant results. This is one reason identifying elevated Lp(a) now matters, even before widely available treatment options exist.
Dietary change matters, but differently
For someone with a genetic cholesterol condition, rigid dietary restriction is not the main event. It can help at the margins. But it cannot fix what medication is designed to fix.
The liver of a person with FH overproduces LDL regardless of how much saturated fat they eat. Eliminating butter, cake, and cheese entirely might lower LDL by 10 to 15 percent. A PCSK9 inhibitor on top of a statin might lower it by 70 to 80 percent. If your cholesterol problem is genetic, pharmacological treatment is doing most of the work, and it should be.
This does not mean diet is irrelevant. Eating in a way that reduces inflammation, with plenty of vegetables, fish, olive oil, and whole grains, supports everything else. The Mediterranean dietary pattern has direct evidence for plaque stabilization that operates through mechanisms beyond LDL alone. But the framing shifts from “if I just ate perfectly, this would resolve” to “medication manages the underlying driver, and reasonable eating supports the whole picture.” For patients who have been living under the anxiety of believing every food choice is a crisis, that reframe matters.
You do not have to give up cake entirely. You do have to take your medication.
The rest of the family needs to know
A genetic finding in one person is clinical information for their relatives. First-degree relatives of someone diagnosed with FH, including parents, siblings, and children, have a 50 percent chance of carrying the same mutation. Children in particular benefit from early identification: catching FH before decades of elevated LDL have accumulated allows treatment to begin early and substantially reduces lifetime cardiovascular risk.
Cascade screening, the practice of testing family members once a diagnosis is made, is recommended by guidelines but still underutilized in practice. A care team can help facilitate referrals and coordination.
What Ongoing Care Looks Like with a Genetic Cardiac Risk
A genetic cardiovascular condition is a long-term management situation, not something that gets solved once and closed out. Genetic heart disease cannot always be prevented outright, but its impact can be substantially reduced through early detection and consistent treatment, which is a meaningfully different goal than prevention and one that is realistically achievable for most patients. LDL targets need regular monitoring. Medication doses may need adjustment. New medications are becoming available, particularly for Lp(a). Cardiovascular risk factors that interact with genetic predisposition, including blood pressure, glucose regulation, and inflammation markers, all benefit from consistent attention.
This is exactly the kind of care that chronic care management is designed to support. Monthly check-ins with a care team, medication reviews, coordination with specialists, and a care plan that evolves as the clinical picture changes, these are the structures that make long-term management genuinely manageable rather than overwhelming.
For Medicare patients, POD Health’s chronic care management and remote patient monitoring programs provide this kind of consistent, between-visit support, working alongside whatever specialist care a cardiologist is providing.
How POD Health Supports Medicare Patients Managing Genetic Heart Disease
If you have received a cardiac CT finding that your doctor described as unexpected, or if you have been told your cholesterol levels do not match your lifestyle, ask whether a genetic component might be part of the picture. It is a reasonable question and a straightforward one to investigate.
POD Health works with Medicare patients to support complex cardiac and chronic care across all five boroughs of New York City, including Staten Island, Brooklyn, Queens, the Bronx, and Manhattan, as well as Westchester County, Florida, and Colorado. Through our chronic care management program, our dedicated team can help you understand your results, coordinate genetic testing where appropriate, and build a care plan that accounts for what is actually driving your risk.
Managing genetic heart disease is not a solo problem. It is support from someone who knows your situation. Contact us to find out if you qualify through Medicare, often at little to no out-of-pocket cost depending on your coverage.
